Balanced news tone
News Sentiment
009420 sentiment intelligence
Hanall Biopharma Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
50
Balanced news tone
6 relevant articles
News tone and price action are not far from neutral.
85/100 classification confidence.
directly relevant articles
high-authority source matches
-1.4% over one week, -10.9% over four weeks, trend active, and materially above fair value.
Daewoong takes over Turn Bio’s longevity platform from Hanall
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
85/100 classification
One-week reaction
-1.4%
Price digesting
Trend fit
Trend active
-10.9% over four weeks
Fair value
38.3%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
0
Neutral
6
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
BioWorld News
Direct company coverage
Daewoong takes over Turn Bio’s longevity platform from Hanall
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 May 2026 07:00
- Source
- BioWorld News
PR Newswire
Direct company coverage
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 May 2024 07:00
- Source
- PR Newswire
BioSpace
Direct company coverage
HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical Study of HL192
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Oct 2023 07:00
- Source
- BioSpace
PR Newswire
Direct company coverage
HanAll Biopharma and Daewoong Pharmaceutical Co-invest in Vincere Biosciences for Collaborative Opportunities in Parkinson's Disease
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 12 Jun 2023 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 25 May 2023 07:00
- Source
- PR Newswire
PR Newswire
Direct company coverage
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Feb 2023 08:00
- Source
- PR Newswire